Ondansteron: Difference between revisions
(added page) |
Elcatracho (talk | contribs) |
||
| (14 intermediate revisions by 9 users not shown) | |||
| Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: | *Type: [[antiemetics]] | ||
*Dosage Forms: | *Dosage Forms: 4mg, 8mg | ||
*Common Trade Names: Zofran | *Common Trade Names: Zofran | ||
==Adult Dosing== | ==Adult Dosing== | ||
*Nausea/Vomiting: 4-8mg q4h, max 24mg a day | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*Nausea/Vomiting: 0.1mg/kg IV q4h max dose at once:4-8mg, max 24mg | |||
*Gastroenteritis - Vomiting | |||
**8 to 15 kg: | |||
***2mg orally disintegrating tablet dissolved orally as a single dose | |||
**15 to 30 kg: | |||
***4mg orally disintegrating tablet dissolved orally as a single dose | |||
**Greater than 30 kg: | |||
***8mg orally disintegrating tablet dissolved orally as a single dose | |||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B | ||
*Lactation: | **Consider avoiding in 1st trimester; conflicting data regarding possible risk of teratogenicity | ||
*Renal Dosing | **Newer data argues that ondansetron is not the cause of birth defects<ref>Fejzo MS, et al. Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States. Reprod Toxicol. 2016 Jul;62:87-91.</ref> | ||
**Adult | *Lactation:safety unknown | ||
**Pediatric | *Renal Dosing: | ||
*Hepatic Dosing | **Adult: not defined | ||
**Adult | **Pediatric: not defined | ||
**Pediatric | *Hepatic Dosing: not defined | ||
**Adult: not defined | |||
**Pediatric: not defined | |||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug | ||
*Congenital long QT syndrome | |||
*Serotonin syndrome | |||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*bronchospasm | |||
*steven-johnson syndrome | |||
*QT prolongation | |||
*torsades de pointes | |||
*serotonin syndrome | |||
*extrapyramidal symptoms | |||
*blindness, transient | |||
===Common=== | ===Common=== | ||
*headache | |||
*constipation | |||
*fatigue | |||
*hypoxia | |||
*fever | |||
*urinary retention | |||
*agitation | |||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 4.6-5.7 hour | ||
*Metabolism: | *Metabolism: liver | ||
*Excretion: | *Excretion: urine | ||
*Mechanism of Action: | *Mechanism of Action:selectively antagonizes serotonin 5-HT3 receptors | ||
==See Also== | ==See Also== | ||
==References== | |||
<references/> | <references/> | ||
[[Category: | |||
[[Category:Pharmacology]] | |||
[[Category:GI]] | |||
Latest revision as of 12:23, 6 March 2021
General
- Type: antiemetics
- Dosage Forms: 4mg, 8mg
- Common Trade Names: Zofran
Adult Dosing
- Nausea/Vomiting: 4-8mg q4h, max 24mg a day
Pediatric Dosing
- Nausea/Vomiting: 0.1mg/kg IV q4h max dose at once:4-8mg, max 24mg
- Gastroenteritis - Vomiting
- 8 to 15 kg:
- 2mg orally disintegrating tablet dissolved orally as a single dose
- 15 to 30 kg:
- 4mg orally disintegrating tablet dissolved orally as a single dose
- Greater than 30 kg:
- 8mg orally disintegrating tablet dissolved orally as a single dose
- 8 to 15 kg:
Special Populations
- Pregnancy Rating: B
- Consider avoiding in 1st trimester; conflicting data regarding possible risk of teratogenicity
- Newer data argues that ondansetron is not the cause of birth defects[1]
- Lactation:safety unknown
- Renal Dosing:
- Adult: not defined
- Pediatric: not defined
- Hepatic Dosing: not defined
- Adult: not defined
- Pediatric: not defined
Contraindications
- Allergy to class/drug
- Congenital long QT syndrome
- Serotonin syndrome
Adverse Reactions
Serious
- bronchospasm
- steven-johnson syndrome
- QT prolongation
- torsades de pointes
- serotonin syndrome
- extrapyramidal symptoms
- blindness, transient
Common
- headache
- constipation
- fatigue
- hypoxia
- fever
- urinary retention
- agitation
Pharmacology
- Half-life: 4.6-5.7 hour
- Metabolism: liver
- Excretion: urine
- Mechanism of Action:selectively antagonizes serotonin 5-HT3 receptors
See Also
References
- ↑ Fejzo MS, et al. Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States. Reprod Toxicol. 2016 Jul;62:87-91.